

When TAVI Is Not a Good Indication



Didier TCHETCHE,

Clinique Pasteur, Toulouse.





GRCI France 2018

CONFLICTS OF INTEREST RELATED TO THE CONTENT OF THE PRESENTATION

Intervenant : Didier TCHÉTCHÉ, Toulouse Cedex 3

☑ Disclosure:

Proctoring/Consulting fees: Boston Scientific, Edwards Lifesciences, Medtronic, Abbott Vascular



Who is a good TAVI candidate?





Severe symptomatic aortic stenosis

Inoperable patient

High surgical risk

Heart team assessment

Life-expectancy> 1 year





EuroIntervention 2018;14:e380-e382 published online e-edition July 2018 TAVI durability beyond five years: no alarms, but stay alert





Age: should we treat (very) old patients?






Add life to years and not years to life









* Adapted from United States Social Security Life Tables (F. Bell and M. Miller)

Implementation of a geriatrician into the heart team decision Pasteur

- Denied patient
 - 91 years old
 - female
- Comorbidities
 - •Previous CABG
 - LVEF 45%
 - Acute pulmonary oedema
 - Euroscore 23%
 - STS 10 %
 - Limited autonomy
 - Institution



- Selected patient
 - 92 years old
 - male
- Comorbidities
 - •Previous CABG
 - LVEF 40 %
 - Acute pulmonary oedema
 - Euroscore 29%
 - STS 11 %
 - •Generally active
 - •Living with his wife






Age: should we treat young patients?




TAVI durability up to 5 years



Mack et al., Lancet 2015

CoreValve CE Pivotal Trial



Kovac, Presented at ACC 2014

GRCI France 2018

CLINIQUE Pasteur

Ś

53

46


5

56

48



Freedom from THV degeneration



THV degeneration was defined as at least moderate regurgitation AND/OR mean gradient ≥ 20mmHg, which did not appear within 30 days of the procedure and is not related to endocarditis. KM estimate of THV degeneration included censoring of patients at their date of last known THV functioning well without evidence for degeneration per study definition.




SAPIEN Platform Durability: testing up to 9 Years

1st generation



Horse pericardium Untreated

2nd generation SAPIEN




Bovine pericardium Anticalcification treatment

Valves explanted after 7 years



Vancouver 9 year durability experience



Vancouver

- 9 year experience
- >1,000 implants
- 5 failed valves




TAVI Durability Example

2005: CoreValve case in Caracas.

Jose Condado, MD.

CoreValve 25 Fr




SOFI

News	Latest news	The News
Ź	Archives	Two-Month Follow-up of first South-American patient shows 58-year-old female is fully recovered and has resumed normal activity after non-surgical replacement of defective aortic heart valve using Corevalve's breakthrough ReValving™ procedure
	2012	
	2011	
	2010	
	2009	04/04/2005
	2008	One of an ongoing series of early cases that demonstrate
	2007	CoreValve's ReValving™ approach is a successful alternative to
	2006	open-heart surgery
	2005	"This patient's life has been transformed—without
	2004	surgery—from being significantly debilitated to normal-
	2003	functioning as a direct result of ReValving. The procedure was
		nerformed in a hosnital cathlab (not a cardiac OR) and avoided



2015: 10 y Follow up







Key Message

Age per se is not a limit for TAVI

Lack of autonomy /Severe cognitive dysfunction

Life-expectancy< 1 year


Young patients: more durability data required



How about the risk profile?











Impact on the STS score on 2-Year All-Cause Mortality CoreValve ADVANCE Registry





Adverse impact of Risk scores on survival: Sapien experience



R. Makkar et al. JACC 2014;63:901-911



Key Message

Patients with higher risk scores may not be good candidates for TAVI

Logistic EuroSCORE>50 STS score>15






Technical aspects



Very tortuous anatomy






Combinaison Flex-Tension guide

CI France 2018




Very tortuous anatomy







A valve-in-valve at high risk of coronary obstruction







GRCI France 2018

Key Message

Procedural outcomes depend on the appropriateness of the access route and the techniques anticipated for TAVI

Surgery may be a better option in some High risk patients



Conclusion





Patients with (very) short or long life-expectancy

Patients with limited autonomy

Patients with extremely high risk scores

Too challenging anatomical conditions

There is no consensus in the Heart Team









MERCI THANK YOU DANKE どうもありがとう GRACIAS 谢谢 **OBRIGADO** GRAZIE BEDANKT DEKUJI Спасибо **EFHARISTO**

